Abstract

While effective targeted delivery is a challenge in nanomedicine for the delivery of anti-cancer drugs, this work focuses on the potential use of Bismuthene and antimonene nanosheets as nanocarriers for cisplatin anti-cancer using DFT methods. The results indicate that, compared to antimonene, bismuthene demonstrates significantly better physical stability, drug release rate, solubility, and biocompatibility, making it an excellent candidate for drug delivery systems. The parallel and perpendicular orientations of the anticancer drug were adsorbed on both nanosheets; the parallel configuration was the most energetically favored with an adsorption energy of −0.79 eV at the parallel site. A charge transfer from the drug to the bismuthene sheet is also revealed by the electronic charge analysis and DOS calculation, thus confirming efficient drug adsorption. Modeling a proton attack on the drug and the carrier surface near the adsorption sites was performed to model drug release, showing the stability and potential of bismuthene in this aspect of drug release mechanisms. Further, with an approach to studying its interactions with biomolecules, interactions of the drug molecule have been analyzed with amino acids, showing that drugs interact efficiently. Further assessments concerning work function, recovery time, electron localization function, and frontier molecular orbital analyses leave no doubt that bismuthene has beneficial features over antimonene. These thorough assessments present bismuthene as a more promising nanocarrier for the delivery of anti-cancer drugs and open a potential pathway to enhance the efficacy of strategies against cancer treatment.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.